# Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

> **NCT07564232** · PHASE1 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** LNK001

## Key facts

- **NCT ID:** NCT07564232
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2031-06-06
- **Final completion:** 2033-06-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07564232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07564232, "Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07564232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*